Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, sprycel®) a potent, orally bioavailable inhibitor of several ty...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Dunn, Emily F., Iida, Mari, Myers, Rebecca A., Hintz, Kylee A., Campbell, David A., Armstrong, Eric A., Li, Chunrong, Wheeler, Deric L.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3025039/
https://ncbi.nlm.nih.gov/pubmed/20956938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2010.430
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires